The Ipsen Group publishes its 2011 Registration document

Regulatory News:

Ipsen (Paris:IPN) (Euronext: IPN; ADR: IPSEY) announced today that its 2011 Registration Document has been filed with the French "Autorité des Marchés Financiers (AMF)" on 29 March 2012 and registered under the number D.12-0236.

The document is available on the Company's website: www.ipsen.com and on the AMF's website: www.amf-france.org. Copies are also available at Ipsen's headquarters – 65 quai Georges Gorse, 92650 Boulogne-Billancourt cedex – France.

The following documents are incorporated into the 2011 Registration Document:

• The Annual Financial Report;
• The Chairman's Report on the preparation and organisation of the works of the Board of Directors and internal control procedures and risk management proceduresand the corresponding Statutory Auditor's report;
• The information relating to the fees paid to the Statutory Auditors;
• The Annual Information Report.

About Ipsen

Ipsen is a global specialty-driven pharmaceutical company with total sales exceeding €1.1 billion in 2011. Ipsen's ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by four franchises: neurology / Dysport^®, endocrinology / Somatuline^®, uro-oncology / Decapeptyl^® and hemophilia. Moreover, the Group has an active policy of partnerships. R&D is focused on innovative and differentiated technological patient-driven platforms, peptides and toxins. In 2011, R&D expenditure totaled more than €250 million, above 21% of Group sales. The Group has total worldwide staff of close to 4,500 employees. Ipsen's shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and eligible to the "Service de Règlement Différé" ("SRD"). The Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I American Depositary Receipt (ADR) program, which trade on the over-the-counter market in the United States under the symbol IPSEY. For more information on Ipsen, visit www.ipsen.com.

Contacts:

Ipsen
Media
Didier Véron
Vice-President, Public Affairs and Corporate Communications
Tel.: [phone]
Fax: [phone]
E-mail: [e-mail]
or
Financial Community
Pierre Kemula
Vice-President Investor Relations
Tel.: [phone]
Fax: [phone]
E-mail: [e-mail]
or
Stéphane Durant des Aulnois
Investor Relations Manager
Tel.: [phone]
Fax: [phone]
E-mail: [e-mail]